High Potency API /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech (Biologic, Biosimilar)), Manufacturer (Captive, Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecast to 2021

高力価API(医薬品原薬)の世界市場予測(~2021年)

◆タイトル:High Potency API /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech (Biologic, Biosimilar)), Manufacturer (Captive, Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecast to 2021
◆商品コード:MAM-PH4897
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年1月12日
◆ページ数:216
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、高力価API(医薬品原薬)の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別分析、合成別分析、製造企業別分析、地域別分析、高力価API(医薬品原薬)の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

・イントロダクション
・エグゼクティブサマリー
・高力価API(医薬品原薬)の世界市場:市場インサイト
・高力価API(医薬品原薬)の世界市場:市場概観/市場動向
・高力価API(医薬品原薬)の世界市場:市場シェア分析
・高力価API(医薬品原薬)の世界市場:種類別分析/市場規模
・高力価API(医薬品原薬)の世界市場:合成別分析/市場規模
・高力価API(医薬品原薬)の世界市場:製造企業別分析/市場規模
・高力価API(医薬品原薬)の世界市場:地域別分析/市場規模
・高力価API(医薬品原薬)のアジア市場規模予測
・高力価API(医薬品原薬)のヨーロッパ市場規模予測
・高力価API(医薬品原薬)のアメリカ市場規模予測
・高力価API(医薬品原薬)の世界市場動向
・高力価API(医薬品原薬)の世界市場:競争状況
・高力価API(医薬品原薬)の世界市場:関連企業分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

The global active pharmaceutical ingredients market is expected to reach USD 24.09 Billion by 2021 from USD 16.02 Billion in 2016, growing at a CAGR of 8.5% from 2016 to 2021.
Market growth is driven by the rapid growth in the oncology drugs market, growing demand for antibody drug conjugates, increasing focus of pharmaceutical companies on HPAPIs, and advancements in HPAPI technologies. Furthermore emerging markets and emerging technologies have opened an array of opportunities for the growth of the high potency active pharmaceutical ingredients market. The market also offers lucrative growth opportunities for CMO and CDMOs. However, factors such as stringent regulatory requirements and requirement of large investments may restrain the growth of this market. The active pharmaceutical ingredients market is segmented on the basis type, type of manufacturer, type of synthesis, therapeutic application, and region.

Based on type, the market is segmented into innovative and generic HPAPIs. The innovative HPAPIs segment is expected to account for the largest share in 2016. The large share of this segment is attributed to the presence of large number of patent-protected innovative HPAPIs, their higher price as compared to generics, growing focus of major players on the development of novel high-potency products, and the growing demand for high-potency cancer therapeutics. The generic HPAPIs segment is expected to register the highest growth rate in the forecast period. The impending patent cliff, increasing healthcare costs, and government initiatives to encourage the adoption of generics are the major factors driving the growth of this market segment.

On the basis of type of manufacture, the HPAPIs market is categorized into two segments, captive manufacturer and merchant manufacturer. In 2016, the captive manufacturers segment is estimated to account for the largest share. The large share of this segment is attributed to the preference of innovative companies to maintain in-house manufacturing facilities for their economic benefits. The merchant manufacturers segment is expected to register the highest CAGR during the forecast period. The high growth rate of the merchant manufacturers segment is attributed to the growing trend of outsourcing manufacturing processes.

On the basis of type of synthesis, the HPAPIs market is segmented into synthetic HPAPIs and biotech HPAPIs. The synthetic HPAPIs segment is estimated to command the largest share in 2016. The increasing emergence of new molecules in the market, rising number of new product approvals, technological advancements in synthesis, and ease of production are driving the growth of the synthetic HPAPIs segment. The biotech HPAPIs segment is expected to grow at the highest CAGR during the forecast period. Advances in biotechnology, growing demand for antibody drug conjugates, growing demand due to their specificity in action, their similarity with the natural biological compounds, and significant growth in the demand for monoclonal antibodies are the major factors driving the growth of this market.

On the basis of therapeutic application, the HPAPIs market is further segmented into oncology, hormonal imbalance, glaucoma, and other therapeutic applications. The oncology segment is estimated to account for the largest share of the global HPAPIs market in 2016. The growing incidence and prevalence of cancer across the globe and the launch of new target therapies in addition to technological advancements in the oncology HPAPI-antibody conjugate technology are major factors contributing to the growth of this application segment

The global high potency active pharmaceutical ingredients market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America will continue to lead the global active pharmaceutical ingredients market in the forecast period. Over the next five years, Asia Is expected to register highest growth rate. Factors such as high prevalence of cancer and other lifestyle- and age-related diseases, increase in disposable income, and growing market for merchant manufacturers in this region owing to the low labor and manufacturing costs are driving the growth of the Asian HPAPIs market

Some of the prominent players in the market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).

【レポートの目次】

1 Introduction (Page No. – 21)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Market Stakeholders

2 Research Methodology (Page No. – 25)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Key Data From Secondary Sources
2.4 Insights From Primary Sources
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 32)

4 Premium Insights (Page No. – 37)
4.1 High Potency Active Pharmaceutical Ingredients Market Overview
4.2 High Potency Active Pharmaceutical Ingredients Market, By Type
4.3 High Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis
4.4 High Potency Active Pharmaceutical Ingredients Market, By Therapeutic Area
4.5 High Potency Active Pharmaceutical Ingredients Market: Geographic Snapshot

5 Market Overview (Page No. – 41)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rapid Growth in the Oncology Drugs Market
5.2.1.2 Growing Demand for Antibody Drug Conjugates
5.2.1.3 Increasing Focus of Leading Pharmaceutical Companies on HPAPIs
5.2.1.4 Advancements in HPAPI Manufacturing Technologies
5.2.2 Restraints
5.2.2.1 Stringent Regulatory Requirements
5.2.2.2 Requirement of Large Investments
5.2.3 Opportunities
5.2.3.1 Growing Opportunities for Cmos and Cdmos
5.2.3.2 Emerging Markets
5.2.4 Challenges
5.2.4.1 Stringent Safety and Handling Specifications
5.2.4.2 Uncertainty Associated With Products
5.2.4.3 Need for Appropriate Process Design
5.2.4.4 Constant Evolution of Industry Standards and Technologies

6 High Potency Active Pharmaceutical Ingredients Classification and Overview (Page No. – 49)
6.1 Introduction
6.2 High Potency Active Pharmaceutical Ingredients Classification as Per Safebridge Consultants

7 High Potency Active Pharmaceutical Ingredients Market, By Type (Page No. – 52)
7.1 Introduction
7.2 Innovative High Potency Active Pharmaceutical Ingredients
7.3 Generic High Potency Active Pharmaceutical Ingredients

8 High Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis (Page No. – 60)
8.1 Introduction
8.2 Synthetic High Potency Active Pharmaceutical Ingredients
8.2.1 Synthetic High Potency Active Pharmaceutical Ingredients Market, By Type
8.2.1.1 Innovative Synthetic HPAPIs
8.2.1.2 Generic Synthetic HPAPIs
8.3 Biotech High Potency Active Pharmaceutical Ingredients
8.3.1 Biotech High- otency Active Pharmaceutical Ingredients Market, By Type
8.3.1.1 Innovative Biotech HPAPIs
8.3.1.2 Biosimilars

9 High Potency Active Pharmaceutical Ingredients Market, By Type of Manufacturer (Page No. – 77)
9.1 Introduction
9.2 Captive Manufacturers
9.3 Merchant Manufacturers
9.3.1 Merchant HPAPI Manufacturers Market, By Type
9.3.1.1 Innovative Merchant HPAPI Manufacturers
9.3.1.2 Generic Merchant HPAPI Manufacturers
9.3.2 Merchant HPAPI Manufacturers Market, By Type of Synthesis
9.3.2.1 Synthetic HPAPIs
9.3.2.2 Biotech HPAPIs

10 High Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application (Page No. – 93)
10.1 Introduction
10.2 Oncology
10.3 Hormonal Imbalance
10.4 Glaucoma
10.5 Other Therapeutic Applications

11 High Potency Active Pharmaceutical Ingredients Market, By Region (Page No. – 104)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 U.K.
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest of Europe (RoE)
11.4 Asia
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Rest of Asia (RoA)
11.5 Rest of the World (RoW)

12 Competitive Landscape (Page No. – 166)
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Situation and Trends
12.3.1 Agreements, Collaborations, Partnerships, and Alliances
12.3.2 Mergers and Acquisitions
12.3.3 Regulatory Approvals
12.3.4 Expansions

13 Company Profiles (Page No. – 172)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 Introduction
13.2 Pfizer, Inc.
13.3 Novartis International AG
13.4 Sanofi
13.5 F. Hoffmann-La Roche Ltd.
13.6 Bristol-Myers Squibb
13.7 Boehringer Ingelheim
13.8 Teva Pharmaceutical Industries Ltd.
13.9 ELI Lilly and Company
13.10 Merck & Co., Inc.
13.11 Abbvie Inc.
13.12 Mylan N.V.

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

14 Appendix (Page No. – 200)
14.1 Insights From Industry Experts
14.2 Discussion Guide
14.3 Other Developments
14.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.5 Introducing RT: Real-Time Market Intelligence
14.6 Available Customizations
14.7 Related Reports
14.8 Author Details

List of Tables (221 Tables)

Table 1 Rapidly Growing Oncology Drugs Segment: A Major Market Driver
Table 2 Stringent Regulatory Requirements: A Major Restraint for Market Growth
Table 3 Emerging Markets to Offer Potential Growth Opportunities
Table 4 Stringent Safety and Handling Specifications: A Major Challenge for Market Growth
Table 5 Market Size, By Type, 2014-2021 (USD Million)
Table 6 Innovative Market Size, By Region, 2014-2021 (USD Million)
Table 7 North America: Innovative Market Size, By Country, 2014-2021 (USD Million)
Table 8 Europe: Innovative Market Size, By Country, 2014-2021 (USD Million)
Table 9 Asia: Innovative Market Size, By Country, 2014-2021 (USD Million)
Table 10 Generic Market, By Region, 2014-2021 (USD Million)
Table 11 North America: Generic Market Size, By Country, 2014-2021 (USD Million)
Table 12 Europe: Generic Market Size, By Country, 2014-2021 (USD Million)
Table 13 Asia: Generic Market Size, By Country, 2014-2021 (USD Million)
Table 14 Market Size, By Type of Synthesis 2014-2021 (USD Million)
Table 15 Synthetic Market Size, By Region, 2014-2021 (USD Million)
Table 16 North America: Synthetic Market Size, By Country, 2014-2021 (USD Million)
Table 17 Europe: Synthetic Market Size, By Country, 2014-2021 (USD Million)
Table 18 Asia: Synthetic Market Size, By Country, 2014-2021 (USD Million)
Table 19 Synthetic Market Size, By Type, 2014-2021 (USD Million)
Table 20 Innovative Synthetic Market, By Region, 2014-2021 (USD Million)
Table 21 North America: Innovative Synthetic Market Size, By Country, 2014-2021 (USD Million)
Table 22 Europe: Innovative Synthetic Market Size, By Country, 2014-2021 (USD Million)
Table 23 Asia: Innovative Synthetic Market Size, By Country, 2014-2021 (USD Million)
Table 24 Generic Synthetic Market, By Region, 2014-2021 (USD Million)
Table 25 North America: Generic Synthetic Market Size, By Country, 2014-2021 (USD Million)
Table 26 Europe: Generic Synthetic Market Size, By Country, 2014-2021 (USD Million)
Table 27 Asia: Generic Synthetic Market Size, By Country, 2014-2021 (USD Million)
Table 28 Biotech Market Size, By Region, 2014-2021 (USD Million)
Table 29 North America: Biotech Market Size, By Country, 2014-2021 (USD Million)
Table 30 Europe: Biotech Market Size, By Country, 2014-2021 (USD Million)
Table 31 Asia: Biotech Market Size, By Country, 2014-2021 (USD Million)
Table 32 Biotech Market Size, By Type, 2014-2021 (USD Million)
Table 33 Innovative Biotech Market, By Region, 2014-2021 (USD Million)
Table 34 North America: Innovative Biotech Market Size, By Country, 2014-2021 (USD Million)
Table 35 Europe: Innovative Biotech Market Size, By Country, 2014-2021 (USD Million)
Table 36 Asia: Innovative Biotech Market Size, By Country, 2014-2021 (USD Million)
Table 37 Biosimilars Market, By Region, 2014-2021 (USD Million)
Table 38 North America: Biosimilars Market Size, By Country, 2014-2021 (USD Million)
Table 39 Europe: Biosimilars Market Size, By Country, 2014-2021 (USD Million)
Table 40 Asia: Biosimilars Ingredients Market Size, By Country, 2014-2021 (USD Million)
Table 41 Market Size, By Type of Manufacturer, 2014-2021 (USD Million)
Table 42 Captive HPAPI Manufacturers Market Size, By Region, 2014-2021 (USD Million)
Table 43 North America: Captive HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 44 Europe: Captive HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 45 Asia: Captive HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 46 Merchant HPAPI Manufacturers Market Size, By Region, 2014-2021 (USD Million)
Table 47 North America: Merchant HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 48 Europe: Merchant HPAPI Manufacturer Market Size, By Country, 2014-2021 (USD Million)
Table 49 Asia: Merchant HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 50 Global Merchant HPAPI Manufacturers Market, By Type, 2014-2021, (USD Million)
Table 51 Innovative Merchant HPAPI Manufacturers Market Size, By Region, 2014-2021 (USD Million)
Table 52 North America: Innovative Merchant HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 53 Europe: Innovative Merchant HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 54 Asia: Innovative Merchant HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 55 Generic Merchant HPAPI Manufacturers Market Size, By Region, 2014-2021 (USD Million)
Table 56 North America: Generic Merchant HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 57 Europe: Generic Merchant HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 58 Asia: Generic Merchant HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 59 Global Merchant HPAPI Manufacturers Market, By Type of Synthesis, 2014-2021, (USD Million)
Table 60 Merchant Synthetic HPAPI Manufacturers Market Size, By Region, 2014-2021 (USD Million)
Table 61 North America: Merchant Synthetic HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 62 Europe: Merchant Synthetic HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 63 Asia: Merchant Synthetic HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 64 Merchant Biotech HPAPI Manufacturers Market, By Region, 2014-2021 (USD Million)
Table 65 North America: Merchant Biotech HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 66 Europe: Merchant Biotech HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 67 Asia: Merchant Biotech HPAPI Manufacturers Market Size, By Country, 2014-2021 (USD Million)
Table 68 Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 69 Market Size for Oncology, By Region, 2014–2021 (USD Million)
Table 70 North America: Market Size for Oncology, By Country, 2014–2021 (USD Million)
Table 71 Europe: Market Size for Oncology, By Country, 2014–2021 (USD Million)
Table 72 Asia: Market Size for Oncology, By Country, 2014–2021 (USD Million)
Table 73 Market Size for Hormonal Imbalance, By Region, 2014–2021 (USD Million)
Table 74 North America: Market Size for Hormonal Imbalance, By Country, 2014–2021 (USD Million)
Table 75 Europe: Market Size for Hormonal Imbalance, By Country, 2014–2021 (USD Million)
Table 76 Asia: Market Size for Hormonal Imbalance, By Country, 2014–2021 (USD Million)
Table 77 Market Size for Glaucoma, By Region, 2014–2021 (USD Million)
Table 78 North America: Market Size for Glaucoma, By Country, 2014–2021 (USD Million)
Table 79 Europe: Market Size for Glaucoma, By Country, 2014–2021 (USD Million)
Table 80 Asia: Market Size for Glaucoma, By Country, 2014–2021 (USD Million)
Table 81 Market Size for Other Therapeutic Applications, By Region, 2014–2021 (USD Million)
Table 82 North America: Market Size for Other Therapeutic Applications, By Country, 2014–2021 (USD Million)
Table 83 Europe: Market Size for Other Therapeutic Applications, By Country, 2014–2021 (USD Million)
Table 84 Asia: Market Size for Other Therapeutic Applications, By Country, 2014–2021 (USD Million)
Table 85 Global Market Size, By Region, 2014–2021 (USD Million)
Table 86 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 87 North America: Market Size, By Type, 2014–2021 (USD Million)
Table 88 North America: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 89 North America: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 90 North America: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 91 North America: Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 92 North America: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 93 North America: Biotech Market Size, By Type, 2014–2021 (USD Million)
Table 94 North America: Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 95 U.S.: Market Size, By Type, 2014–2021 (USD Million)
Table 96 U.S.: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 97 U.S.: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 98 U.S.: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 99 U.S.: Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 100 U.S.: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 101 U.S.: Biotech Market Size, By Type, 2014–2021 (USD Million)
Table 102 U.S.: Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 103 Canada: Market Size, By Type, 2014–2021 (USD Million)
Table 104 Canada: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 105 Canada: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 106 Canada: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 107 Canada: Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 108 Canada: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 109 Canada: Biotech Market Size, By Type, 2014–2021 (USD Million)
Table 110 Canada: Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 111 Europe: Market Size, By Country, 2014–2021 (USD Million)
Table 112 Europe: Market Size, By Type, 2014–2021 (USD Million)
Table 113 Europe: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 114 Europe: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 115 Europe: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 116 Europe: Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 117 Europe: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 118 Europe: Biotech Market Size, By Type, 2014–2021 (USD Million)
Table 119 Europe: Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 120 Germany: Market Size, By Type, 2014–2021 (USD Million)
Table 121 Germany: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 122 Germany: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 123 Germany: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 124 Germany: Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 125 Germany: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 126 Germany: Biotech Market Size, By Type, 2014–2021 (USD Million)
Table 127 Germany: Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 128 France: Market Size, By Type, 2014–2021 (USD Million)
Table 129 France: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 130 France: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 131 France: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 132 France: Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 133 France: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 134 France: Biotech Market Size, By Type, 2014–2021 (USD Million)
Table 135 France: Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 136 U.K.: Market Size, By Type, 2014–2021 (USD Million)
Table 137 U.K.: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 138 U.K.: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 139 U.K.: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 140 U.K.: Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 141 U.K.: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 142 U.K.: Biotech Market Size, By Type, 2014–2021 (USD Million)
Table 143 U.K.: Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 144 Italy: Market Size, By Type, 2014–2021 (USD Million)
Table 145 Italy: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 146 Italy: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 147 Italy: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 148 Italy: Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 149 Italy: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 150 Italy: Biotech Market Size, By Type, 2014–2021 (USD Million)
Table 151 Italy: Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 152 Spain: Market Size, By Type, 2014–2021 (USD Million)
Table 153 Spain: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 154 Spain: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 155 Spain: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 156 Spain: High Potency API Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 157 Spain: Synthetic High Potency API Market Size, By Type, 2014–2021 (USD Million)
Table 158 Spain: Biotech High Potency API Market Size, By Type, 2014–2021 (USD Million)
Table 159 Spain: High Potency API Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 160 RoE: High Potency API Market Size, By Type, 2014–2021 (USD Million)
Table 161 RoE: High Potency API Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 162 RoE: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 163 RoE: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 164 RoE: High Potency API Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 165 RoE: Synthetic High Potency API Market Size, By Type, 2014–2021 (USD Million)
Table 166 RoE: Biotech High Potency API Market Size, By Type, 2014–2021 (USD Million)
Table 167 RoE: High Potency API Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 168 Asia: High Potency API Market Size, By Type, 2014–2021 (USD Million)
Table 169 Asia: High Potency API Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 170 Asia: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 171 Asia: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 172 Asia: High Potency API Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 173 Asia: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 174 Asia: Biotech High Potency API Market Size, By Type, 2014–2021 (USD Million)
Table 175 Asia: High Potency API Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 176 Japan: High Potency API Market Size, By Type, 2014–2021 (USD Million)
Table 177 Japan: High Potency API Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 178 Japan: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 179 Japan: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 180 Japan: High Potency API Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 181 Japan: Synthetic Market Size, By Type, 2014–2021 (USD Million)
Table 182 Japan: Biotech Market Size, By Type, 2014–2021 (USD Million)
Table 183 Japan: Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 184 China: Market Size, By Type, 2014–2021 (USD Million)
Table 185 China: Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 186 China: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 187 China: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 188 China: Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 189 China: Synthetic High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 190 China: Biotech High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 191 China: High Potency Active Pharmaceutical Ingredients Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 192 India: High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 193 India: High Potency Active Pharmaceutical Ingredients Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 194 India: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 195 India: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 196 India: High Potency Active Pharmaceutical Ingredients Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 197 India: Synthetic High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 198 India: Biotech High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 199 India: High Potency Active Pharmaceutical Ingredients Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 200 RoA: High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 201 RoA: High Potency Active Pharmaceutical Ingredients Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 202 RoA: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 203 RoA: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 204 RoA: High Potency Active Pharmaceutical Ingredients Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 205 RoA: Synthetic High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 206 RoA: Biotech High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 207 RoA: High Potency Active Pharmaceutical Ingredients Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 208 RoW: High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 209 RoW: High Potency Active Pharmaceutical Ingredients Market Size, By Type of Manufacturer, 2014–2021 (USD Million)
Table 210 RoW: Merchant Manufacturers Market Size, By HPAPI Type, 2014–2021 (USD Million)
Table 211 RoW: Merchant Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 212 RoW: High Potency Active Pharmaceutical Ingredients Market Size, By Mode of Synthesis, 2014–2021 (USD Million)
Table 213 RoW: Synthetic High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 214 RoW: Biotech High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Million)
Table 215 RoW: High Potency Active Pharmaceutical Ingredients Market Size, By Therapeutic Application, 2014–2021 (USD Million)
Table 216 Agreements, Collaborations, Partnerships, and Alliances (2013–2016)
Table 217 Mergers and Acquisitions (2013-2016)
Table 218 Regulatory Approvals (2013-2016)
Table 219 Expansions (2013–2016)
Table 220 Exchange Rate (Utilized for the Conversion of Eur to USD)
Table 221 Exchange Rates (Utilized for the Conversion of Chf to USD)

List of Figures (44 Figures)

Figure 1 Research Design
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 High Potency Active Pharmaceutical Ingredients Market Size, By Type, 2016 vs 2021
Figure 7 High Potency Active Pharmaceutical Ingredients Market Size, By Type of Manufacturer, 2016 vs 2021
Figure 8 High Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2016 vs 2021
Figure 9 High Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application: Oncology Segment to Dominate the Market in 2016
Figure 10 Geographic Snapshot of the High Potency Active Pharmaceutical Ingredients Market
Figure 11 Rising Need to Comply With Regulatory Requirements, the Major Factor Driving the Growth of the Market
Figure 12 Innovative High Potency Active Pharmaceutical Ingredients to Account for the Largest Market Share in 2016
Figure 13 Biotech High Potency Active Pharmaceutical Ingredients Segment to Witness Highest Growth During the Forecast Period
Figure 14 Oncology Segment to Witness Highest Growth During the Forecast Period
Figure 15 China to Witness Highest Growth During 2012–2021
Figure 16 Active Pharmaceutical Ingredients Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 High Potency Active Pharmaceutical Ingredients Market Segmentation, By Type
Figure 18 Innovative Segment to Dominate the Active Pharmaceutical Ingredients Market, By Type, in 2016
Figure 19 Synthetic Segment to Dominate the Market in 2016
Figure 20 North America to Hold Largest Share in the Synthetic High Potency Active Pharmaceutical Ingredients Market in 2016
Figure 21 Captive Manufacturers to Hold Largest Share of the Market in 2016
Figure 22 North America to Dominate the Captive Manufacturers Market in 2016
Figure 23 Oncology to Dominate the High Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application (2016)
Figure 24 Asia to Witness Highest Growth During the Forecast Period (2016–2021)
Figure 25 North America: High Potency Active Pharmaceutical Ingredients Market Snapshot (2016)
Figure 26 Europe: High Potency Active Pharmaceutical Ingredients Market Snapshot
Figure 27 Asia: High Potency Active Pharmaceutical Ingredients Market Snapshot
Figure 28 Rest of the World: High Potency Active Pharmaceutical Ingredients Market Snapshot
Figure 29 Key Developments in the High Potency Active Pharmaceutical Ingredients Market, 2013–2016
Figure 30 Market Evolution Framework— Agreements, Collaborations, Partnerships, and Alliances Fueled Market Growth
Figure 31 Market Share Analysis: Oncology Segment, By Key Player, 2015
Figure 32 Battle for Market Share: Agreements, Collaborations, Partnerships, and Alliances Was the Key Strategy Adopted By Market Players (2013–2016)
Figure 33 Geographic Mix of the Top 5 Players
Figure 34 Pfizer, Inc.: Company Snapshot
Figure 35 Novartis International AG: Company Snapshot
Figure 36 Sanofi: Company Snapshot
Figure 37 F. Hoffmann-La Roche Ltd.: Company Snapshot
Figure 38 Bristol-Myers Squibb: Company Snapshot
Figure 39 Boehringer Ingelheim: Company Snapshot
Figure 40 Teva Pharmaceutical Industries Ltd.: Company Snapshot
Figure 41 ELI Lilly and Company: Company Snapshot
Figure 42 Merck & Co., Inc.: Company Snapshot
Figure 43 Abbvie Inc.: Company Snapshot
Figure 44 Mylan Inc.: Company Snapshot

【レポートのキーワード】

高力価API、医薬品原薬、合成、バイオ技術、製造、治療

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[高力価API(医薬品原薬)の世界市場予測(~2021年)]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆